Hot Products

Bortezomib (PS-341)
Catalog No: CFN60019

Bortezomib (PS-341, LDP-341, MLM341) is a potent 20S proteasome inhibitor with Ki of 0.6 nM. It exhibits favorable selectivity towards tumor cells over normal cells. Bortezomib (PS-341) inhibits NF-κB and induces ERK phosphorylation to suppress cathepsin B and inhibit the catalytic process of autophagy in ovarian cancer and other solid tumors.
Brandioside
Catalog No: CFN90882

Brandioside shows strong antioxidant, and neuroprotective effects, it significantly attenuates glutamate-induced neurotoxicity at concentrations ranging from 0.1 to 10 microM; it exhibits significant inhibition of advanced glycation end product formation with the IC50 value of 4.6-25.7 uM. Brandioside shows inhibition of smooth muscle cell proliferation, indicates that it may have preventative effects on arteriosclerosis.
Brassicasterol
Catalog No: CFN90471

Brassicasterol may be a relevant additional biomarker in Alzheimer's disease (AD).
Brazilin
Catalog No: CFN98711

Brazilin exhibits cancer preventive, anti-hepatotoxicity, antiplatelet activity, and anti-inflammatory activities, it also inhibits UVB-induced MMP-1/3 expressions and secretions by suppressing of NF-κB activation in human dermal fibroblasts, thus, it might be used as a potential agent for treatment of UV-induced skin photoaging. Brazilin has anti-IKK activity, can selectively disrupt proximal IL-1 receptor signaling complex formation by targeting an IKK-upstream signaling components. Brazilin induces vasorelaxation by the increasing intracellular Ca(2+) concentration in endothelial cells of blood vessels and hence activating Ca(2+)/calmodulin-dependent NO synthesis.
Brevifolincarboxylic acid
Catalog No: CFN93653

Brevifolincarboxylic acid shows moderate antibacterial activity against Salmonella enteritidis , Salmonella typhimurium , and Salmonella abony, it (IC50 = 18.0 uM) also shows good antioxidant activity. Brevifolincarboxylic acid shows marked inhibitory effects on aryl hydrocarbon receptor -based bioassay activation by TCDD, and its effect is dose dependent.
Brevilin A
Catalog No: CFN99694

Brevilin A is a strong impetus for the development of selective JAK-STAT inhibitors and therapeutic drugs in order to improve survival of patients with hyperactivated JAKs and STATs. Brevilin A shows antigiardial activity (IC50 = 16.1 μM) and is similarly active in vitro against Entamoeba histolytica (IC50 between 4.5 and 9 μM) and against Plasmodium falciparum (IC50 = 9.42 μM).
Breviscapine
Catalog No: CFN90315

Breviscapine can reduce the inflammatory response, protect the lungs from inflammatory cascade responses by inhibiting the expression of IL-18 and ICAM-1. Breviscapine inhibits the increased levels of 4-HNE and 8-OHdG, and enhances the antioxidant capacity of cortex tissue. Breviscapine can treat coronary disease, breviscapine injection significantly ameliorates neurologic deficit, reduces infarct volume and water content, and suppresses the levels of NSE in a time-dependent manner, may the mechanism is by up-regulating the expression of Nrf2/HO-1 pathway .
Britannilactone
Catalog No: CFN92601

Britannilactone significantly reduces melanin production in a dose-dependent manner with the IC50 value of 15.5 uM.
Britannin
Catalog No: CFN90220

Britannin has strong cytotoxicity to HepG-2, MCF-7, MDBK and A-549 cells (IC50: 2.2, 5.9, 5.4, and 3.5 microg/mL, respectively). Britannin inhibits growth of MCF-7 and MDA-MB-468 breast cancer cells through the activation of the mitochondrial apoptotic pathway and may potentially serve as an agent for breast cancer therapy.
Broussoflavonol B
Catalog No: CFN92774

Broussoflavonol B is a potent growth inhibitor of ER-negative breast cancer stem-like cells, may be used to treat breast cancer. Broussoflavonol B increases the growth inhibitory activity of tamoxifen in tumorsphere cells derived from MCF7/TAM cells.